The local medical sector is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for treating obesity. This treatment promises a https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/